Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD1-PASC I
NCT07388550Phase 1Not yet recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in post acute COVID-19 syndrome, sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Number of adverse events and serious adverse events at 180 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT07388550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388550.